Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
126.45
+0.60 (+0.48%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
17
18
Next >
MarketBeat: Week in Review 10/17-10/21
October 22, 2022
Stocks are staging a rally to end the week. But economic data next week may bring more volatility. Here are some of the most popular articles from this week
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
October 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
October 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
October 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
October 06, 2022
From
Merck & Co., Inc.
Via
Business Wire
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
September 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
September 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
September 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
September 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health to Acquire Vence
September 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
September 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
September 22, 2022
From
Merck & Co., Inc. Merck
Via
Business Wire
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
September 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
September 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
September 12, 2022
Via
JCN Newswire
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
September 12, 2022
From
Seagen Inc.
Via
Business Wire
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
September 11, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
September 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials
September 09, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care
September 08, 2022
From
Merck Foundation
Via
Business Wire
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Merck & Co., Inc.
Via
Business Wire
Monkeypox vaccine and research related stocks taking center stage (VRAX,GOVX,TNXP,APDN)
September 02, 2022
Via
AB Newswire
Exposures
COVID-19
Merck Reports Strong Progress in ESG Focus Areas
August 30, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
August 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
August 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
August 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
August 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
August 11, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.